Business
Jaguar Health Provides Company Updates and Reports 2022 Third Quarter Financials
Prescription product net revenue of approximately $3.1 million in Q3 2022 increased 8.2% over Q2 2022 and increased approximately 412% over prescription
About this update from Jaguar Health, Inc.
[{"type":"text","content":"Prescription product net revenue of approximately $3.1 million in Q3 2022 increased 8.2% over Q2 2022 and increased approximately 412% over prescription product net revenue in Q3 2021Core initiatives:OnTarget Phase 3 clinical trial of crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD) adding international sites, targeting completion of enrollment in Q2 2023Publication of Phase 2 IIT study in peer reviewed journal Breast Cancer Research and TreatmentExpected presentation in December 2022 from a third-party investigator, Dr. Mohamad Miqdady, Division Chief of the Pediatric Gastroenterology, Hepatology & Nutrition Division at Sheikh Khalifa Medical City in Abu Dhabi, following initiation of proof-of-concept trial of crofelemer for short bowel syndrome (SBS) and congenital diarrheal disorders (CCD), supporting the potential for expanded patient access through programs in Europe in 2023Second conditional approval for Canalevia®, for exercise-induced diarrhea (EID), expected in Q1 2023, adding to ongoing commercial activities of Canalevia-CA1 for treatment of chemotherapy-induced diarrhea (CID) in dogsBusiness development activities with nondilutive funding for Jaguar's mental health Entheogen Therapeutics Initiative (ETI) program targeted for Q1 2023Jaguar's Canine Cancer: Take C.H.A.R.G.E. Registry honored by the MarCom Awards program with two Platinum awards and one Gold awardREMINDER: Jaguar to host investor webcast Monday, November 14th at 8:30 a.m. Eastern regarding third quarter 2022 financials and company updates; Click here to register for webcastSAN FRANCISCO, CA / ACCESSWIRE / November 14, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) (\"Jaguar\" or the \"Company\") today provided Company updates and reported consolidated third-quarter 2022 financial results.The combined net revenue for Mytesi® and the Company's other prescription product, Canalevia®-CA1, which became commercially available in April 2022, was approximately $3.1 million in the third quarter of 2022, representing an increase of 8.2% over prescription product net revenue in the second quarter of 2022, which totaled approximately $2.9 million, and an increase of approximately 412% over Mytesi net revenue in the third quarter of 2021, which totaled approximately $0.6 million.\"We are very pleased that growth in Mytesi (crofelemer) revenue continued f...